Phaseline

Companies › HUYABIO International

HUYABIO International: clinical trials, targets and expected readouts

4 active drug programs in 4 registered trials: 2 Phase 1, 1 Phase 2, 1 Phase 3; Oncology, Cardiovascular; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
HBI-8000
Histone deacetylase inhibitor
HDACPhase 3Unresectable or Metastatic MelanomaDec 2026
HBI-3000
Multi-ion channel blocker
–Phase 2Atrial Fibrillation–
HBI-2376
SHP2 inhibitor
PTPN11Phase 1Non Small Cell Lung CancerDec 2026
HBI-2438
KRAS G12C inhibitor
KRASPhase 1Lung CancerDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04680026HBI-3000Phase 2Atrial FibrillationCardiovascularDec 2025
NCT04674683HBI-8000Phase 3Unresectable or Metastatic MelanomaOncologyDec 2026
NCT05163028HBI-2376Phase 1Non Small Cell Lung CancerOncologyDec 2026
NCT05485974HBI-2438Phase 1Lung CancerOncologyDec 2026

Targets

PTPN11 (1) KRAS (1) HDAC (1)

Companies with the same targets

Revolution Medicines Novartis TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) Quanta Therapeutics Roche Eli Lilly Allist Pharmaceuticals Bristol-Myers Squibb Amgen Astellas

Companies built like this

Allist Pharmaceuticals BeBetter Med Blueprint Medicines Genfleet Therapeutics (Shanghai) CStone Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.